Patient characteristics: uptake of FLT in malignant lymphoma before (baseline) and during therapy as well as response to therapy
| Patient . | Age (y) . | Histology . | Clinical stage . | Day 0 . | Day 2 . | Day 4 . | Day 7 . | Day 40 . | Response* . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | DLBCL | IBE | 2.6 | 2.5 | 1.0 | — | — | CR |
| 2 | 69 | DLBCL | IVAE | 8.5 | 6.6 | 2.8 | — | — | PR |
| 3 | 76 | DLBCL | IAE | 11.8 | 10.4 | — | — | — | PR |
| 4 | 29 | DLBCL | IAE | 4.7 | 4.9 | — | — | — | CR |
| 5 | 71 | DLBCL | IAE | 19.4 | 16.3 | 3.0 | — | — | PR |
| 6 | 76 | DLBCL | IAE | 13.8 | 10.4 | — | — | — | CR |
| 7 | 27 | DLBCL | IAE | 8.0 | 7.8 | 1.8 | — | — | CR |
| 8 | 62 | DLBCL | IIIAE | 8.3 | 8.2 | 3.1 | — | — | PR |
| 9 | 55 | DLBCL | IA | 10.5 | 11.5 | — | — | — | CR |
| 10 | 69 | DLBCL | IVA | 14.8 | 14.3 | 9.0 | — | — | PD |
| 11 | 65 | DLBCL | IAE | 6.9 | 6.5 | — | — | — | |
| 12 | 63 | FL grade 3 | IVA | 7.6 | 2.1 | — | — | — | CR |
| 13 | 55 | DBLCL | IA | 7.2 | 2.7 | — | — | — | PR |
| 14 | 74 | DBLCL | IA | 5.8 | 6.2 | 1.5 | — | — | CR |
| 15 | 69 | DBLCL | IA | 7.7 | 10.6 | 1.4 | — | — | CR |
| 16 | 76 | DLBCL | IAE | 6.9 | — | — | 1.8 | 1.4 | CR |
| 17 | 48 | DLBCL | IAE | 8.2 | — | — | 2.0 | 1.0 | CR |
| 18 | 46 | FL grade 3 | IVAE | 4.7 | — | — | 1.4 | 0.7 | CR |
| 19 | 34 | Anaplastic T-cell | IIIA | 6.2 | — | — | 1.0 | 0.8 | CR |
| 20 | 63 | DLBCL | IAE | 5.8 | 2.4 | 2.1 | — | — | CR |
| 21 | 70 | DLBCL | IVAE | 5.1 | — | — | 1.3 | — | PR |
| 22 | 56 | Anaplastic T-cell | IIIA | 4.6 | — | — | 0.7 | — | CR |
| Patient . | Age (y) . | Histology . | Clinical stage . | Day 0 . | Day 2 . | Day 4 . | Day 7 . | Day 40 . | Response* . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 51 | DLBCL | IBE | 2.6 | 2.5 | 1.0 | — | — | CR |
| 2 | 69 | DLBCL | IVAE | 8.5 | 6.6 | 2.8 | — | — | PR |
| 3 | 76 | DLBCL | IAE | 11.8 | 10.4 | — | — | — | PR |
| 4 | 29 | DLBCL | IAE | 4.7 | 4.9 | — | — | — | CR |
| 5 | 71 | DLBCL | IAE | 19.4 | 16.3 | 3.0 | — | — | PR |
| 6 | 76 | DLBCL | IAE | 13.8 | 10.4 | — | — | — | CR |
| 7 | 27 | DLBCL | IAE | 8.0 | 7.8 | 1.8 | — | — | CR |
| 8 | 62 | DLBCL | IIIAE | 8.3 | 8.2 | 3.1 | — | — | PR |
| 9 | 55 | DLBCL | IA | 10.5 | 11.5 | — | — | — | CR |
| 10 | 69 | DLBCL | IVA | 14.8 | 14.3 | 9.0 | — | — | PD |
| 11 | 65 | DLBCL | IAE | 6.9 | 6.5 | — | — | — | |
| 12 | 63 | FL grade 3 | IVA | 7.6 | 2.1 | — | — | — | CR |
| 13 | 55 | DBLCL | IA | 7.2 | 2.7 | — | — | — | PR |
| 14 | 74 | DBLCL | IA | 5.8 | 6.2 | 1.5 | — | — | CR |
| 15 | 69 | DBLCL | IA | 7.7 | 10.6 | 1.4 | — | — | CR |
| 16 | 76 | DLBCL | IAE | 6.9 | — | — | 1.8 | 1.4 | CR |
| 17 | 48 | DLBCL | IAE | 8.2 | — | — | 2.0 | 1.0 | CR |
| 18 | 46 | FL grade 3 | IVAE | 4.7 | — | — | 1.4 | 0.7 | CR |
| 19 | 34 | Anaplastic T-cell | IIIA | 6.2 | — | — | 1.0 | 0.8 | CR |
| 20 | 63 | DLBCL | IAE | 5.8 | 2.4 | 2.1 | — | — | CR |
| 21 | 70 | DLBCL | IVAE | 5.1 | — | — | 1.3 | — | PR |
| 22 | 56 | Anaplastic T-cell | IIIA | 4.6 | — | — | 0.7 | — | CR |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CR, complete response; PR, partial response; PD, progressive disease.
Response after completion of six cycles of R-CHOP/CHOP.